Irritable Bowel Syndrome and Digestive Health Support Forum banner
1 - 1 of 1 Posts

·
Banned
Joined
·
0 Posts
Discussion Starter · #1 ·
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has submitted an efficacy supplement to NDA 21-361 for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating...View the full article
 
1 - 1 of 1 Posts
This is an older thread, you may not receive a response, and could be reviving an old thread. Please consider creating a new thread.
Top